Effects of almond consumption on metabolic function and liver fat in overweight and obese adults with elevated fasting blood glucose: A randomised controlled trial

Jane Bowen, Natalie D. Luscombe-Marsh, Welma Stonehouse, Cuong Tran, Geraint Rogers, Nathan Johnson, Campbell H. Thompson, Grant D. Brinkworth

Research output: Contribution to journalArticle

Abstract

Background: Almonds are a rich source of bioactive components. This study examined the effects of daily almond consumption on glycaemic regulation, liver fat concentration and function, adiposity, systemic inflammation and cardiometabolic health. Methods: 76 adults with elevated risk of type 2 diabetes (T2D) or T2D (age: 60.7 ± 7.7 years, body mass index: 33.8 ± 5.6 kg/m 2 ) were randomly assigned to daily consumption of either 2 servings of almonds (AS:56 g/day) or an isocaloric, higher carbohydrate biscuit snack (BS) for 8 weeks. Glycosylated haemoglobin (HbA1c), glycaemic variability (GV), liver fat, serum aminotransferases, body weight and composition, markers of cardio-metabolic risk and systemic inflammation were assessed at baseline and week 8. Results: No group differential effects were observed on HbA1c, GV, body weight and composition, liver fat and aminotransferases, cardio-metabolic health and inflammatory markers (all P > 0.05). For serum TC/HDL-C ratio a significant gender × treatment × time interaction occurred (P < 0.01), such that in women TC/HDL-C ratio was significantly reduced after AS compared to BS (−0.36 [0.26] mmol/L [n = 14] vs. −0.14 [0.32] mmol/L [n = 17]; P = 0.05), but not in men (P = 0.52). Conclusions: Compared to BS, AS consumed between meals did not substantially alter glycaemic regulation, liver fat or function, adiposity, and metabolic health and inflammatory markers. Serum TC/HDL-C ratio improved in women, but not in men with AS; but as this sub-analysis was not defined a priori the results should be interpreted with caution. Further research should examine the longer-term health effects of regular almond consumption and differential gender responses. Clinical trial registry number and website: Australia New Zealand Clinical Trial Registry: ACTRN12616000571471 (https://www.anzctr.org.au).

LanguageEnglish
Pages10-18
Number of pages9
JournalClinical Nutrition ESPEN
Volume30
DOIs
Publication statusPublished - 1 Apr 2019

Keywords

  • Adiposity
  • Diet
  • Glucose metabolism
  • Glucose variability
  • Inflammation
  • Lipids
  • Liver fat
  • Nuts
  • Obesity
  • Overweight

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

Bowen, Jane ; Luscombe-Marsh, Natalie D. ; Stonehouse, Welma ; Tran, Cuong ; Rogers, Geraint ; Johnson, Nathan ; Thompson, Campbell H. ; Brinkworth, Grant D. / Effects of almond consumption on metabolic function and liver fat in overweight and obese adults with elevated fasting blood glucose : A randomised controlled trial. In: Clinical Nutrition ESPEN. 2019 ; Vol. 30. pp. 10-18.
@article{38511b6ebec84e4f996b17eb30856626,
title = "Effects of almond consumption on metabolic function and liver fat in overweight and obese adults with elevated fasting blood glucose: A randomised controlled trial",
abstract = "Background: Almonds are a rich source of bioactive components. This study examined the effects of daily almond consumption on glycaemic regulation, liver fat concentration and function, adiposity, systemic inflammation and cardiometabolic health. Methods: 76 adults with elevated risk of type 2 diabetes (T2D) or T2D (age: 60.7 ± 7.7 years, body mass index: 33.8 ± 5.6 kg/m 2 ) were randomly assigned to daily consumption of either 2 servings of almonds (AS:56 g/day) or an isocaloric, higher carbohydrate biscuit snack (BS) for 8 weeks. Glycosylated haemoglobin (HbA1c), glycaemic variability (GV), liver fat, serum aminotransferases, body weight and composition, markers of cardio-metabolic risk and systemic inflammation were assessed at baseline and week 8. Results: No group differential effects were observed on HbA1c, GV, body weight and composition, liver fat and aminotransferases, cardio-metabolic health and inflammatory markers (all P > 0.05). For serum TC/HDL-C ratio a significant gender × treatment × time interaction occurred (P < 0.01), such that in women TC/HDL-C ratio was significantly reduced after AS compared to BS (−0.36 [0.26] mmol/L [n = 14] vs. −0.14 [0.32] mmol/L [n = 17]; P = 0.05), but not in men (P = 0.52). Conclusions: Compared to BS, AS consumed between meals did not substantially alter glycaemic regulation, liver fat or function, adiposity, and metabolic health and inflammatory markers. Serum TC/HDL-C ratio improved in women, but not in men with AS; but as this sub-analysis was not defined a priori the results should be interpreted with caution. Further research should examine the longer-term health effects of regular almond consumption and differential gender responses. Clinical trial registry number and website: Australia New Zealand Clinical Trial Registry: ACTRN12616000571471 (https://www.anzctr.org.au).",
keywords = "Adiposity, Diet, Glucose metabolism, Glucose variability, Inflammation, Lipids, Liver fat, Nuts, Obesity, Overweight",
author = "Jane Bowen and Luscombe-Marsh, {Natalie D.} and Welma Stonehouse and Cuong Tran and Geraint Rogers and Nathan Johnson and Thompson, {Campbell H.} and Brinkworth, {Grant D.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.clnesp.2018.12.088",
language = "English",
volume = "30",
pages = "10--18",
journal = "Clinical Nutrition ESPEN",
issn = "2405-4577",
publisher = "Elsevier Ltd",

}

Effects of almond consumption on metabolic function and liver fat in overweight and obese adults with elevated fasting blood glucose : A randomised controlled trial. / Bowen, Jane; Luscombe-Marsh, Natalie D.; Stonehouse, Welma; Tran, Cuong; Rogers, Geraint; Johnson, Nathan; Thompson, Campbell H.; Brinkworth, Grant D.

In: Clinical Nutrition ESPEN, Vol. 30, 01.04.2019, p. 10-18.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of almond consumption on metabolic function and liver fat in overweight and obese adults with elevated fasting blood glucose

T2 - Clinical Nutrition ESPEN

AU - Bowen, Jane

AU - Luscombe-Marsh, Natalie D.

AU - Stonehouse, Welma

AU - Tran, Cuong

AU - Rogers, Geraint

AU - Johnson, Nathan

AU - Thompson, Campbell H.

AU - Brinkworth, Grant D.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Background: Almonds are a rich source of bioactive components. This study examined the effects of daily almond consumption on glycaemic regulation, liver fat concentration and function, adiposity, systemic inflammation and cardiometabolic health. Methods: 76 adults with elevated risk of type 2 diabetes (T2D) or T2D (age: 60.7 ± 7.7 years, body mass index: 33.8 ± 5.6 kg/m 2 ) were randomly assigned to daily consumption of either 2 servings of almonds (AS:56 g/day) or an isocaloric, higher carbohydrate biscuit snack (BS) for 8 weeks. Glycosylated haemoglobin (HbA1c), glycaemic variability (GV), liver fat, serum aminotransferases, body weight and composition, markers of cardio-metabolic risk and systemic inflammation were assessed at baseline and week 8. Results: No group differential effects were observed on HbA1c, GV, body weight and composition, liver fat and aminotransferases, cardio-metabolic health and inflammatory markers (all P > 0.05). For serum TC/HDL-C ratio a significant gender × treatment × time interaction occurred (P < 0.01), such that in women TC/HDL-C ratio was significantly reduced after AS compared to BS (−0.36 [0.26] mmol/L [n = 14] vs. −0.14 [0.32] mmol/L [n = 17]; P = 0.05), but not in men (P = 0.52). Conclusions: Compared to BS, AS consumed between meals did not substantially alter glycaemic regulation, liver fat or function, adiposity, and metabolic health and inflammatory markers. Serum TC/HDL-C ratio improved in women, but not in men with AS; but as this sub-analysis was not defined a priori the results should be interpreted with caution. Further research should examine the longer-term health effects of regular almond consumption and differential gender responses. Clinical trial registry number and website: Australia New Zealand Clinical Trial Registry: ACTRN12616000571471 (https://www.anzctr.org.au).

AB - Background: Almonds are a rich source of bioactive components. This study examined the effects of daily almond consumption on glycaemic regulation, liver fat concentration and function, adiposity, systemic inflammation and cardiometabolic health. Methods: 76 adults with elevated risk of type 2 diabetes (T2D) or T2D (age: 60.7 ± 7.7 years, body mass index: 33.8 ± 5.6 kg/m 2 ) were randomly assigned to daily consumption of either 2 servings of almonds (AS:56 g/day) or an isocaloric, higher carbohydrate biscuit snack (BS) for 8 weeks. Glycosylated haemoglobin (HbA1c), glycaemic variability (GV), liver fat, serum aminotransferases, body weight and composition, markers of cardio-metabolic risk and systemic inflammation were assessed at baseline and week 8. Results: No group differential effects were observed on HbA1c, GV, body weight and composition, liver fat and aminotransferases, cardio-metabolic health and inflammatory markers (all P > 0.05). For serum TC/HDL-C ratio a significant gender × treatment × time interaction occurred (P < 0.01), such that in women TC/HDL-C ratio was significantly reduced after AS compared to BS (−0.36 [0.26] mmol/L [n = 14] vs. −0.14 [0.32] mmol/L [n = 17]; P = 0.05), but not in men (P = 0.52). Conclusions: Compared to BS, AS consumed between meals did not substantially alter glycaemic regulation, liver fat or function, adiposity, and metabolic health and inflammatory markers. Serum TC/HDL-C ratio improved in women, but not in men with AS; but as this sub-analysis was not defined a priori the results should be interpreted with caution. Further research should examine the longer-term health effects of regular almond consumption and differential gender responses. Clinical trial registry number and website: Australia New Zealand Clinical Trial Registry: ACTRN12616000571471 (https://www.anzctr.org.au).

KW - Adiposity

KW - Diet

KW - Glucose metabolism

KW - Glucose variability

KW - Inflammation

KW - Lipids

KW - Liver fat

KW - Nuts

KW - Obesity

KW - Overweight

UR - http://www.scopus.com/inward/record.url?scp=85059690292&partnerID=8YFLogxK

U2 - 10.1016/j.clnesp.2018.12.088

DO - 10.1016/j.clnesp.2018.12.088

M3 - Article

VL - 30

SP - 10

EP - 18

JO - Clinical Nutrition ESPEN

JF - Clinical Nutrition ESPEN

SN - 2405-4577

ER -